|
18 Feb 2022 |
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
|
|
17 Feb 2022 |
Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis
|
|
17 Feb 2022 |
Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma
|
|
17 Feb 2022 |
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
|
|
17 Feb 2022 |
LEXEO Therapeutics Announces FDA Clearance of Investigational New Drug Application for LX2006, an AAV-based Gene Therapy Candidate for Friedreich’s Ataxia Cardiomyopathy
|
|
16 Feb 2022 |
Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
|
|
16 Feb 2022 |
Myrtelle Announces Positive Preliminary Clinical Data for Its Proprietary Gene Therapy in Canavan Disease
|
|
16 Feb 2022 |
Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901
|
|
13 Feb 2022 |
REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
|
|
12 Feb 2022 |
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
|
|
10 Feb 2022 |
REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022
|
|
09 Feb 2022 |
Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel
|
|
09 Feb 2022 |
Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)
|
|
09 Feb 2022 |
enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
|
|
08 Feb 2022 |
Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease
|
|
04 Feb 2022 |
Medigene reports preliminary efficacy and immune monitoring data of Phase I of Phase I/II MDG1011 trial in blood cancers
|
|
03 Feb 2022 |
eTheRNA Announces Research Agreement with Merck KGaA, Darmstadt, Germany to access mRNA technologies
|
|
03 Feb 2022 |
LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program
|
|
02 Feb 2022 |
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
|
|
01 Feb 2022 |
Minerva Biotechnologies Announces Opening 1st-In-Human Phase I/II Trial of a MUC1* Targeting CAR T for Metastatic Breast Cancers at City of Hope
|
|
01 Feb 2022 |
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer
|
|
01 Feb 2022 |
Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors
|
|
01 Feb 2022 |
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy
|
|
31 Jan 2022 |
Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
|
|
28 Jan 2022 |
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
|
